In the absence of a submission from the holder of the marketing authorisation.
Palifermin (Kepivance) is not recommended for use within NHS Scotland for the treatment of oral mucositis in bone marrow transplantation.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice29KB (PDF)
- Medicine name:
- Palifermin (Kepivance®)
- SMC ID:
- Oral mucositis in bone marrow transplantation
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 08 May 2006